miR-29a, miR-29b, and miR-29c were downregulated in PBMCs and bone marrow CD34+ cells in AML patients as opposed to healthy donors (33, 42, 74, 75) miR-29b targeted DNA methyltransferases (DNMTs) DNMT3A and DNMT3B, by reducing the global DNA methylation and specificity protein (SP)1) and DNMT1, by targeting SP1 and enhancing tumor cell chemosensitivity (76, 77). Here, SP1 is linked to acute myeloid leukemia.